Skip to main content

Table 1 Baseline clinical, demographic, biochemical and angiographic features of patients in different SYNTAX score (SS) groups

From: Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction

Variables Total (N = 332) SS ≤ 12 (n = 114) 12 < SS ≤ 21.5 (n = 113) SS > 21.5 (n = 105) P-value
Age (years) 39.30 (4.50) 39.30 (4.70) 39.60 (4.70) 39.10 (3.90) 0.57
Body mass index, kg/m2 25.00 (2.51) 25.28 (2.70) 24.64 (2.30) 25.06 (2.51) 0.46
SBP, mmHg 132.50 (23.20) 132.80 (21.40) 133.20 (24.30) 131.30 (24.20) 0.96
DBP, mmHg 81.0 (14.7) 80.2 (14.5) 84.1 (15.1) 78.5 (14.2) 0.07
Past history
 Hypertension 148 (44.60) 44 (39.00) 49 (43.40) 55 (52.10) 0.26
 Diabetes 46 (13.80) 8 (7.00) 12 (10.60) 27 (25.70) < 0.01*
 Familial hypercholesterolemia 0 (0) 0 (0) 0 (0) 0 (0)
 Familial PCAD 34 (10.30) 16 (14.00) 9 (8.00) 9 (8.60) 0.36
 Smoking 256 (77.10) 89 (78.10) 83 (73.50) 84 (80.00) 0.63
MI type
 STEMI 289 (87.10) 95 (83.30) 96 (85.00) 98 (93.30) 0.18
 NSTEMI 43 (12.90) 19 (16.70) 17 (15.00) 7 (6.70)  
Biochemistry
 White blood cells, 109/L 11.45 (3.12) 11.23 (3.29) 11.20 (2.56) 11.95 (3.46) 0.21
 Urea, mmol/L 4.69 (1.64) 4.48 (2.34) 4.55 (1.70) 5.05 (1.89) 0.05
 Lp(a), nmol/L 21.15 (51.38) 19.00 (33.65) 18.05 (51.58) 24.95 (53.63) 0.28
 TC, mmol/L 5.01 (1.12) 4.84 (0.98) 4.98 (1.19) 5.22 (1.16) 0.11
 LDL-C, mmol/L 3.35 (1.04) 3.18 (0.92) 3.26 (0.98) 3.63 (1.17) 0.02*
 VLDL-C, mmol/L 0.49 (0.48) 0.55 (0.53) 0.48 (0.48) 0.49 (0.43) 0.87
 HDL-C, mmol/L 0.96 (0.31) 0.98 (0.42) 0.92 (0.25) 0.97 (0.20) 0.25
 Triglycerides, mmol/L 2.11 (1.49) 2.12 (1.35) 2.11 (1.53) 2.09 (1.42) 0.99
 Apob, g/L 1.20 (0.30) 1.15 (0.27) 1.17 (0.29) 1.29 (0.32) < 0.01*
 ALT, U/L 54.10 (41.55) 48.75 (47.45) 55.55 (39.98) 54.5 (41.78) 0.97
 Glucose, mmol/L 5.62 (2.93) 5.52 (1.88) 5.51 (2.35) 6.52 (4.06) 0.04*
 Creatinine, μmol/L 79.54 (19.74) 77.56 (12.30) 76.96 (16.82) 84.44 (27.16) 0.09
Coronary heart disease
 LVEF, % 49.80 (7.70) 51.30 (7.10) 50.40 (7.80) 47.60 (7.70) < 0.01*
 Creatine kinase, U/L 1649.50 (2451.00) 1324.00 (1903.00) 1744.00 (2332.80) 1950.00 (2674.00) 0.18
 CK-MB, U/L 125.5 (189.8) 111.5 (184.0) 121.0 (174.0) 162.0 (249.0) 0.33
 c-Tnt, ng/mL 3.57 (5.14) 2.61 (5.38) 3.47 (4.62) 4.01 (5.14) 0.15
 hs-Crp, mg/L 6.18 (13.01) 6.70 (15.04) 5.55 (11.68) 5.92 (13.06) 0.88
 NT-proBnp, pg/mL 446.0 (832.4) 407.6 (809.8) 437.5 (789.5) 528.1 (905.2) 0.29
Prior drug use
 Statin 0 (0) 0 (0) 0 (0) 0 (0)
 Ezetimibe 0 (0) 0 (0) 0 (0) 0 (0)
 Beta-blocker 44 (13.30) 16 (14.00) 14 (12.40) 14 (13.30) 0.22
 CCB 34 (10.20) 11 (9.70) 14 (12.40) 9 (8.60) 0.45
 ARB/ACEI 32 (9.70) 9 (7.90) 11 (9.70) 12 (11.40) 0.31
Biomarker
 Pcsk9, ng/mL 175.66 (92.9) 160.72 (71.39) 170.21 (112.64) 197.95 (87.38) < 0.01*
  1. Variables are presented as mean (SD), median (IQR), or n (%), P-values were derived from one-way analysis of variance, the Kruskal-Wallis test or χ2 test. * P < 0.05
  2. SBP systolic blood pressure, DBP diastolic blood pressure, PCAD premature coronary artery disease, Lp(a) lipoprotein a, TC total cholesterol, LDL-C low density lipoprotein cholesterol, Apob apolipoprotein B, HDL-C high density lipoprotein cholesterol, ALT alanine transaminase, LVEF left ventricular ejection fraction, CK-MB creatine kinase MB, hs-Crp high-sensitivity C-reactive protein, c-Tnt cardiac Troponin T, NT-proBnp N-terminal pro-B type natriuretic peptide, CCB calcium channel blocker, ARB/ACEI angiotensin receptor blocker/angiotensin converting enzyme inhibitor, Pcsk9 proprotein convertase subtilisin/kexin type 9. * P < 0.05